FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasimigton,	D.C.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

vvasilington, D.C. 2004

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	rden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  ADAMS R MARK					2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ ADPT ]									Check	tionship of Reporti all applicable) Director Officer (give title		10% O		
(Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 06/14/2021								X	below	low) below Chief Operating Office			
(Street) SEATTL (City)	E WA		8102 Zip)		4. 11 #	4. If Amendment, Date of Original Filed (Month/Day/Year)								ine)	Form Form	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Table	I - No	on-Deriva	tive S	Secur	ities	Acc	quired	l, Dis	sposed of	, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/N					Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				1 and 5) Sec Ben Owr		mount of urities eficially ned Following orted		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
		Code	v	Amount			(A) or (D)	Price		Transa	nsaction(s) str. 3 and 4)			(111341. 4)					
Common Stock 06/14/20					)21			S <sup>(1)</sup>		8,914	D	\$38.7	<sup>77(2)</sup> 58,10		3,104		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ative Conversion or Execution Date (Month/Day/Year) Frice of Derivative Security		4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)  Amour or Numbe of Title Shares		t		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## **Explanation of Responses:**

- $1. \ The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021.$
- 2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$38.31 to 39.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

## Remarks:

/s/ R. Mark Adams by Eric Billings, attorney-in-fact

06/16/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.